BiotechTube
Ciloa Bio

Ciloa Bio

Montpellier, France· Est.
ciloa.bio
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.5M

Overview

Ciloa Bio is a private, preclinical-stage biotech founded in 2016 and based in Montpellier, France. The company has developed a proprietary platform, EVENGI, for engineering small extracellular vesicles (sEVs) to carry therapeutic payloads, with a lead program (APN-sEVs) targeting obesity and type 2 diabetes. Ciloa has secured significant non-dilutive funding, including a recent €6.5 million grant from France 2030, and engages in strategic partnerships to advance its pipeline in metabolic diseases, vaccines, and oncology.

Metabolic DiseasesOncologyInfectious DiseaseRare DiseasesAge-related Illnesses

Technology Platform

EVENGI platform for the bioengineering, production, purification, and qualification of small extracellular vesicles (sEVs/exosomes). It enables stable loading of therapeutic proteins (e.g., adiponectin) into sEVs, creating targeted natural messengers for drug delivery and vaccination.

Funding History

1
Total raised:$2.5M
Seed$2.5M

Opportunities

The global epidemics of obesity and diabetes present a massive addressable market for a novel, multi-mechanism therapy like APN-sEVs.
The platform's applicability to vaccines offers a high-growth path for pandemic preparedness, and the scalable sEV manufacturing technology itself is a valuable asset for potential partnerships.

Risk Factors

Major risks include the unproven clinical efficacy and safety of engineered exosomes, undefined regulatory pathways for EV-based therapies, and intense competition in the drug delivery and biotherapeutics space.
Future reliance on dilutive financing or partnerships to fund costly clinical trials also presents a financial risk.

Competitive Landscape

Ciloa competes in the rapidly evolving extracellular vesicle therapeutics space against other biotechs like Evox Therapeutics, Codiak BioSciences, and Aruna Bio, as well as large pharma exploring the modality. Differentiation hinges on its specific protein-engineering expertise, scalable production claims, and the unique pharmacological profile of its lead metabolic candidate.

More companies in Drug Delivery & Formulation →More companies in France →